Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Qualidade do Sono Pré-operatória e Resultados Pós-operatórios em Cirurgia da Mama

16 de novembro de 2026 atualizado por: Mustafa Kemal ŞAHİN, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Association of Preoperative Sleep Quality With 24-Hour Systemic Immune-Inflammation Index, Early PACU Pain, and Analgesic Use After Breast Cancer Surgery

This prospective, single-center observational study examined the association between preoperative sleep quality and postoperative outcomes in women undergoing elective breast cancer surgery. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), with scores ≤5 indicating good sleep quality and scores >5 indicating poor sleep quality.

The primary outcome was the systemic immune-inflammation index (SII), calculated from routine blood counts obtained 24 hours after surgery. Postoperative SII was compared between sleep-quality groups, accounting for preoperative SII and relevant clinical and surgical characteristics. Secondary outcomes included change in SII from baseline, pain intensity during the first 45 minutes in the post-anesthesia care unit (PACU), opioid consumption, rescue analgesic requirement, and length of hospital stay. Pain was assessed using a 10-cm visual analogue scale on PACU arrival and at 15, 30, and 45 minutes. Opioid consumption included morphine and tramadol administered during the final 20 minutes of surgery and the first 45 minutes in the PACU, expressed as intravenous morphine equivalents.

No treatment was assigned by the study protocol. Anesthetic and analgesic management followed routine clinical practice.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

This prospective observational study was conducted at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital in Ankara, Turkey, among women undergoing elective breast cancer surgery under general anesthesia. Procedures included lumpectomy or mastectomy, with axillary dissection when clinically indicated. The study examined whether preoperative sleep quality was associated with postoperative systemic immune-inflammation index (SII), immediate postoperative pain, and analgesic use.

Preoperative sleep quality was assessed using the validated Turkish version of the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21, with higher scores indicating poorer sleep quality. Patients were classified as having good sleep quality (PSQI ≤5) or poor sleep quality (PSQI >5). Demographic characteristics, comorbidities, oncological history, surgical characteristics, and perioperative clinical data were recorded prospectively.

The primary outcome was SII measured 24 hours (±6 hours) after surgery, calculated as platelet count × neutrophil count / lymphocyte count. Preoperative SII was calculated using the same formula. The primary analysis compared postoperative SII between sleep-quality groups, adjusting for baseline SII and clinical and surgical covariates. Change in SII, calculated as postoperative minus preoperative SII, was a secondary outcome.

Pain intensity was assessed using a 10-cm visual analogue scale (VAS), anchored at "no pain" and "worst imaginable pain." Patients marked their pain intensity on the line; the distance from the zero anchor was measured and rounded to the nearest whole centimeter. Assessments were performed on arrival in the post-anesthesia care unit (PACU) and at 15, 30, and 45 minutes. Maximum VAS was defined as the highest score across the four scheduled assessments. The pain assessor was unaware of patients' PSQI scores and sleep-quality groups.

Anesthetic and analgesic management followed routine clinical practice, with no treatment assigned by the study protocol. Intravenous morphine or tramadol was administered for postoperative analgesia during the final 20 minutes of surgery. Rescue analgesia consisted of intravenous morphine or tramadol when the PACU VAS score was ≥4; drug selection and dosing were determined by the treating anesthesiologist. Scheduled pain assessments continued after rescue treatment. No regional blocks or surgical local anesthetic infiltration were performed.

Total opioid consumption comprised morphine and tramadol administered during the final 20 minutes of surgery and the first 45 minutes in the PACU. Intravenous tramadol doses were converted to intravenous morphine equivalents using a factor of 0.1 and added to the administered morphine dose. Fentanyl used for induction and remifentanil used for maintenance were excluded from this measure. Rescue analgesic requirement was defined as receipt of at least one rescue opioid dose during the PACU observation period. The planned 24-hour pain and opioid outcomes could not be reliably evaluated because of follow-up limitations and incomplete opioid documentation. The reported analyses were therefore restricted to PACU pain during the first 45 minutes and opioid administration during the final 20 minutes of surgery and this PACU period. Length of hospital stay was also recorded.

Secondary analyses evaluated PSQI total score as a continuous predictor of postoperative SII, maximum VAS, total opioid consumption, and rescue analgesic requirement. Adjustment variables included age, body mass index, ASA physical status III, chronic disease burden, chemotherapy within the previous year, axillary dissection, and operation duration. Breast surgery type was added to the models during manuscript revision. Preoperative SII was included only in the postoperative SII models. Individual covariate-outcome associations were interpreted as exploratory.

Tipo de estudo

Observacional

Inscrição (Real)

156

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Ankara, Turquia (Türkiye), 06200
        • Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Reanimation

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Método de amostragem

Amostra Não Probabilística

População do estudo

The study population included women aged 18-75 years who underwent elective breast cancer surgery at a tertiary oncology center. Procedures included breast-conserving surgery (lumpectomy) or mastectomy, with or without axillary dissection. Preoperative sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). All patients received routine perioperative care, and no treatment was assigned by the study protocol. This observational study examined the association between preoperative sleep quality and postoperative outcomes in routine clinical practice.

Descrição

Inclusion Criteria:

  • Female patients aged 18 to 75 years
  • Scheduled for elective breast cancer surgery
  • American Society of Anesthesiologists (ASA) physical status I to III
  • Able to understand and complete the Pittsburgh Sleep Quality Index (PSQI)
  • Willing to participate in the study
  • Provided written informed consent

Exclusion Criteria:

  • Active infection
  • History of chronic inflammatory disease or autoimmune disease
  • Use of steroids or immunosuppressive drugs within the past 6 months
  • Known diagnosis of obstructive sleep apnea syndrome
  • Severe cognitive impairment preventing completion of the questionnaire
  • Planned emergency surgery
  • Refusal to participate or failure to provide informed consent

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Good Sleep Quality (PSQI ≤ 5)

Patients with good preoperative sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≤5, were included in this cohort. Sleep quality was assessed preoperatively using the validated PSQI questionnaire. No treatment was assigned by the study protocol, and patients received routine perioperative care. Postoperative SII, pain intensity, and analgesic consumption were compared with those in the poor-sleep-quality group.

Preoperative sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated self-reported questionnaire covering the preceding month. Patients were classified into two cohorts: good sleep quality (PSQI ≤5) and poor sleep quality (PSQI >5). The PSQI assessment was used for grouping and analysis. No treatment was assigned by the study protocol, and perioperative management followed routine clinical practice.

Outros nomes:
  • Índice de qualidade do sono de Pittsburgh (PSQI)
Poor Sleep Quality (PSQI > 5)

Patients with poor preoperative sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score >5, were included in this cohort. Sleep quality was assessed preoperatively using the validated PSQI questionnaire. No treatment was assigned by the study protocol, and patients received routine perioperative care. Postoperative SII, pain intensity, and analgesic consumption were compared with those in the good-sleep-quality group.

Preoperative sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated self-reported questionnaire covering the preceding month. Patients were classified into two cohorts: good sleep quality (PSQI ≤5) and poor sleep quality (PSQI >5). The PSQI assessment was used for grouping and analysis. No treatment was assigned by the study protocol, and perioperative management followed routine clinical practice.

Outros nomes:
  • Índice de qualidade do sono de Pittsburgh (PSQI)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Postoperative Systemic Immune-Inflammation Index (SII)
Prazo: At 24 hours postoperatively (± 6 hours)

The primary outcome was the postoperative systemic immune-inflammation index (SII), calculated from routine complete blood count measurements obtained 24 hours after surgery. SII was calculated using the formula: platelet count × neutrophil count / lymphocyte count. Postoperative SII was compared between patients with poor (PSQI >5) and good (PSQI ≤5) preoperative sleep quality, adjusting for preoperative SII and clinical and surgical covariates.

At 24 hours postoperatively (± 6 hours)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in Systemic Immune-Inflammation Index (ΔSII)
Prazo: From the preoperative assessment to 24 hours after surgery.

Change in SII was calculated as postoperative SII minus preoperative SII. SII was calculated at both time points as platelet count × neutrophil count / lymphocyte count. Changes were compared between patients with good (PSQI ≤5) and poor (PSQI >5) preoperative sleep quality.

From the preoperative assessment to 24 hours after surgery.
Immediate Postoperative Pain Intensity
Prazo: On arrival in the post-anesthesia care unit (0 minutes) and at 15, 30, and 45 minutes after arrival.

Pain intensity was assessed using a 10-cm visual analogue scale (VAS), anchored at 0 cm ("no pain") and 10 cm ("worst imaginable pain"). Patients marked their pain intensity on the line, and the measured distance was rounded to the nearest whole centimeter. Scores were recorded at each scheduled assessment, including after rescue analgesia when applicable. Maximum VAS was defined as the highest score across the four assessments

On arrival in the post-anesthesia care unit (0 minutes) and at 15, 30, and 45 minutes after arrival.
Total Opioid Consumption for Postoperative Analgesia
Prazo: From 20 minutes before the end of surgery through the first 45 minutes after PACU arrival.

Total opioid consumption was calculated as the sum of intravenous morphine and tramadol administered for postoperative analgesia during the final 20 minutes of surgery and the first 45 minutes in the post-anesthesia care unit (PACU), including rescue doses. Tramadol doses were multiplied by 0.1 to obtain intravenous morphine equivalents and added to the morphine dose. Consumption was expressed in milligrams of intravenous morphine equivalents. Fentanyl administered during induction and remifentanil used for maintenance were excluded.

From 20 minutes before the end of surgery through the first 45 minutes after PACU arrival.
Rescue Analgesic Requirement
Prazo: Within the first 45 minutes after arrival in the post-anesthesia care unit.

Rescue analgesic requirement was defined as receipt of at least one intravenous dose of morphine or tramadol during the first 45 minutes in the post-anesthesia care unit (PACU). Rescue analgesia was administered when the visual analogue scale (VAS) score was ≥4. Drug selection and dosing were determined by the anesthesiologist responsible for PACU care. The outcome was recorded as yes/no and summarized as the number and percentage of patients receiving rescue analgesia.

Within the first 45 minutes after arrival in the post-anesthesia care unit.
Postoperative Length of Hospital Stay
Prazo: From the date of surgery until hospital discharge, assessed up to 15 days after surgery.

Postoperative length of hospital stay was defined as the duration from the day of breast cancer surgery to hospital discharge, measured in days.

From the date of surgery until hospital discharge, assessed up to 15 days after surgery.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

17 de abril de 2026

Conclusão Primária (Real)

20 de agosto de 2026

Conclusão do estudo (Real)

30 de agosto de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

17 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de abril de 2026

Primeira postagem (Real)

23 de abril de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2026-04/76

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data (IPD) will not be shared. The study involves sensitive clinical data collected from patients in a single-center setting, and data sharing is restricted in order to protect patient confidentiality and comply with institutional and ethical regulations.

De-identified and aggregated data may be available from the corresponding author upon reasonable request, subject to approval by the institutional ethics committee.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .